REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  The results of the MECOMBIN trial of pulsed methylprednisolone plus intramuscular beta-interferon-1a indicate that the combination is not more effective in delaying the onset of disability progression, although improvements in relapse rate and functional scores were observed (Ravnborg et al. ECTRIMS 2009).
Read More

REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Teriflunomide is an immunosuppressant currently being tested in four large phase III trials in clinically isolated syndrome (estimated enrollment 780), MS with relapses (TEMSO trial, estimated n=1080), relapsing-remitting MS (planned n=1110) and versus beta-interferon-1a in RRMS (TENERE trial, estimated n=300).  The drug is the active metabolite of leflunomide that is used in the treatment of rheumatoid arthritis.
Read More

REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  In 2008, the MS Study Group of the Italian Neurological Society reported that one-third of children/adolescents with MS demonstrated cognitive impairments (Amato et al. Neurology 2008; 70: 1891-1897).
Read More

REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009  Alemtuzumab (Campath 1H) is a monoclonal antibody that targets CD52, a cell surface molecule found on thymocytes, lymphocytes, monocytes and eosinophils. Early data suggested that the agent could reduce disability (Coles et al. J Neurol 2006; 253: 98-108), which led to the phase II CAMMS223 trial comparing alemtuzumab with beta-interferon-1a (CAMMS223 Investigators. N Engl J Med 2008; 359: 1786-1801). 
Read More

 REPORT FROM THE 25^th CONGRESS OF THE ECTRIMS – Dusseldorf, Germany, September 9-12, 2009 – Three studies at the 25^th ECTRIMS congress presented new data on vitamin D and multiple sclerosis.

Read More